Fulcrum Therapeutics, Inc. (FULC) income statement
FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$3.72−0.03 (-0.80%)
Close on Nov 18, 2026Market cap $283.83MP/E –Yield –
Fulcrum Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -25.3%
Financial strength
- Current ratio
- 31.35
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 470.6%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.91
- Dividend yield
- –
See a number that looks wrong?